TrialDiabetes care2013

Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.

Bertrand Cariou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.